Drug Trial Radar · NCT06080776
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Last checked: Nov 19, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
242
Planned (sponsor's estimate)
Start
May 11, 2023
Primary completion
Feb 1, 2028
Study completion Feb 1, 2031
Sponsor
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor resection, with or without adjuvant chemotherapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
SH-1028 tabletsDrug
The initial dose of SH-1028 tablets is 200 mg once daily.
Placebo SH-1028 tabletsDrug
Placebo SH-1028 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS) assessed by Independent Review Committee (IRC)Time frame: From the time of randomization to the recurrence of tumor or death, through study completion, an average of 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.